Evidence map›Paper›PMID 38304459›Full record

ArticleFrontiers in cellular and infection microbiology2023

Gut microbiota and its metabolites in non-small cell lung cancer and brain metastasis: from alteration to potential microbial markers and drug targets.

Haixiao Jiang, Wei Zeng, Xiaoli Zhang, Yuping Li, Yilun Wang, Aijun Peng, Demao Cao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Observational
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Omics Approaches to Unraveling the Complexity of the Gut-Lung Axis.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Haixiao Jiang *Department of Neurosurgery, The Affiliated Hospital of Yangzhou University, Yangzhou, China.
Wei Zeng *Department of Neurosurgery, Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School, Yancheng, China.
Xiaoli Zhang *Department of Medical Imaging, The Affiliated Hospital of Yangzhou University, Yangzhou, China.
Yuping LiDepartment of Neurosurgery, Clinical Medical College of Yangzhou University, Yangzhou, China.
Yilun WangDepartment of Thoracic Surgery, Clinical Medical College of Yangzhou University, Yangzhou, China.
Aijun PengDepartment of Neurosurgery, The Affiliated Hospital of Yangzhou University, Yangzhou, China.
Demao CaoDepartment of Neurosurgery, The Affiliated Hospital of Yangzhou University, Yangzhou, China.
Yangzhou University · CNNantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The elevated mortality rate associated with non-small-cell lung cancer (NSCLC) is a well-established global concern. Considerable attention has been directed toward exploring the association between gut microbiota and various malignant tumors. We herein investigated the associations between the intestinal microbiome and its metabolites, particularly short-chain fatty acids (SCFAs), in patients with NSCLC at different stages, including early and brain metastasis (BM) stages. The findings aim to offer a fresh perspective on the diagnosis and management of NSCLC. Methods: Fecal samples were collected from 115 participants, comprising healthy controls (n = 35) and patients with treatment-naive NSCLC at the early stage (ELC, n = 40) and the BM stage (n = 40). Characterization of the intestinal microbiome and fecal SCFA levels was performed using 16S rRNA gene sequencing and gas chromatography. Results: The microbial diversity in patients with NSCLC was found to be less abundant and uniform, particularly in the BM stage. Significant alterations in the community structure of the gut microbiota were observed in patients with NSCLC, with an increase in pathogens in Fusobacteria and Proteobacteria and a decrease in SCFA-producing bacteria in Firmicutes and Actinobacteria, particularly in the BM stage. Meanwhile, microbial communities displayed intricate associations in patients with NSCLC. A biomarker panel ( Conclusion: Compared with healthy controls, distinct host-microbe interactions were evident in different phases of patients with NSCLC. Furthermore, specific forms of the gut microbiome and SCFAs may serve as valuable biomarkers and therapeutic targets in the diagnosis and treatment of NSCLC.

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungGastrointestinal MicrobiomeLung NeoplasmsBacteriaFatty Acids, VolatileFecesHumansRNA, Ribosomal, 16SFatty Acids, VolatileRNA, Ribosomal, 16Sbrain metastasisgut-lung axisgut microbiotalung cancerSCFAs

Identifiers

PMID38304459
PMCPMC10830900
OpenAlexW4390982465

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.